These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52 related articles for article (PubMed ID: 11229619)
1. Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study. Müller MJ; Härtter S; Köhler D; Hiemke C Pharmacopsychiatry; 2001 Jan; 34(1):27-32. PubMed ID: 11229619 [TBL] [Abstract][Full Text] [Related]
2. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Bergemann N; Kopitz J; Kress KR; Frick A Eur Neuropsychopharmacol; 2004 May; 14(3):245-50. PubMed ID: 15056484 [TBL] [Abstract][Full Text] [Related]
3. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. Müller MJ; Regenbogen B; Sachse J; Eich FX; Härtter S; Hiemke C Pharmacopsychiatry; 2006 Mar; 39(2):41-6. PubMed ID: 16555163 [TBL] [Abstract][Full Text] [Related]
4. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. Müller MJ; Eich FX; Regenbogen B; Sachse J; Härtter S; Hiemke C J Psychopharmacol; 2009 May; 23(3):278-86. PubMed ID: 18562411 [TBL] [Abstract][Full Text] [Related]
5. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Olié JP; Spina E; Murray S; Yang R Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136 [TBL] [Abstract][Full Text] [Related]
6. Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Ohnuma T; Sakai Y; Maeshima H; Hatano T; Hanzawa R; Abe S; Kida S; Shibata N; Suzuki T; Arai H Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1905-12. PubMed ID: 18835577 [TBL] [Abstract][Full Text] [Related]
8. [L-sulpiride in the treatment of somatoform disturbances: a double-blind study with racemic sulpiride]. Altamura AC; Mauri MC; Regazzetti G; Coppola MT Minerva Psichiatr; 1991; 32(1):25-9. PubMed ID: 2056888 [TBL] [Abstract][Full Text] [Related]
9. D-serine serum levels in patients with schizophrenia: relation to psychopathology and comparison to healthy subjects. Hons J; Zirko R; Ulrychova M; Cermakova E; Libiger J Neuro Endocrinol Lett; 2008 Aug; 29(4):485-92. PubMed ID: 18766161 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716 [TBL] [Abstract][Full Text] [Related]
11. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial. Lerner V; Miodownik C; Gibel A; Kovalyonok E; Shleifer T; Goodman AB; Ritsner MS Clin Neuropharmacol; 2008; 31(1):25-33. PubMed ID: 18303488 [TBL] [Abstract][Full Text] [Related]
12. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Hashimoto K; Fukushima T; Shimizu E; Komatsu N; Watanabe H; Shinoda N; Nakazato M; Kumakiri C; Okada S; Hasegawa H; Imai K; Iyo M Arch Gen Psychiatry; 2003 Jun; 60(6):572-6. PubMed ID: 12796220 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Müller MJ; Dragicevic A; Fric M; Gaertner I; Grasmäder K; Härtter S; Hermann E; Kuss HJ; Laux G; Oehl W; Rao ML; Rollmann N; Weigmann H; Weber-Labonte M; Hiemke C Pharmacopsychiatry; 2003 May; 36(3):98-104. PubMed ID: 12806567 [TBL] [Abstract][Full Text] [Related]
14. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Rüther E; Degner D; Munzel U; Brunner E; Lenhard G; Biehl J; Vögtle-Junkert U Pharmacopsychiatry; 1999 Jul; 32(4):127-35. PubMed ID: 10505482 [TBL] [Abstract][Full Text] [Related]
15. Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study. Linden M; Scheel T; Xaver Eich F Hum Psychopharmacol; 2004 Mar; 19(2):111-9. PubMed ID: 14994321 [TBL] [Abstract][Full Text] [Related]
16. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048 [TBL] [Abstract][Full Text] [Related]
17. [Drug monitoring of antipsychotics and antidepressants during acute admission in a psychiatric state hospital in Germany]. Vogel M; Köhnlein O; Schmauss M; Messer T Psychiatr Prax; 2004 Nov; 31 Suppl 1():S173-4. PubMed ID: 15570544 [TBL] [Abstract][Full Text] [Related]
18. [Sulpiride: a neuroleptic agent of new generation with unique pharmacological qualities and rather wide range of clinical applications]. Pawłowski L Psychiatr Pol; 1993; 27(2):199-205. PubMed ID: 8104350 [TBL] [Abstract][Full Text] [Related]
19. Effects of melatonin on luteinizing hormone secretion in anestrous ewes following dopamine and opiate receptor blockade. Misztal T; Romanowicz K; Barcikowski B Anim Reprod Sci; 2004 Apr; 81(3-4):245-59. PubMed ID: 14998651 [TBL] [Abstract][Full Text] [Related]
20. Sulpiride addition for the treatment of clozapine-induced hypersalivation: preliminary study. Kreinin A; Epshtein S; Sheinkman A; Tell E Isr J Psychiatry Relat Sci; 2005; 42(1):61-3. PubMed ID: 16134408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]